Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?

To: Sully- who wrote (52928)	6/7/2002 3:21:03 PM
From: Murrey Walker	Read Replies (1) \| Respond to of 65232

...in Texas for a couple of weeks Lived in Dallas for twenty years. Doesn't sound like you'll see much of the state. Two weeks isn't long enough. (g)

To: Sully- who wrote (52928)	6/7/2002 3:21:13 PM
From: stockman_scott	Respond to of 65232

The Science and Technology of Terrorism sciam.com We at ScientificAmerican.com wish to extend our deepest sympathy to those affected by the terrible crashes in New York City, Washington, D.C., and Pennsylvania on September 11, 2001. In the hopes that our past coverage may help readers to make better sense of the science and technology of terrorism, we have put together lists of related links under the following subheadings: Antiterrorism Technology, Biological and Chemical Weapons, The Psychology of Terror, DNA Analysis and PCR and Sky Views: New York City Before and After. In addition, be assured that Scientific American's coverage of this important topic is ongoing. Our most recent news articles appear on this page, as do several highlighted feature stories.

To: Sully- who wrote (52928)	6/7/2002 3:45:09 PM
From: stockman_scott	Respond to of 65232

Here's a firm who's stock is breaking out nicely... eResearch Technology, Inc. (Nasdaq: ERES chart, msgs) provides integrated software applications and technology consulting services to the biotechnology, pharmaceutical and medical-device industries. Their products, designed to streamline clinical trials, use the Internet and other means of electronic data transfer to improve the accuracy, timeliness and efficiency of the various stages of the trials. Revenues for the most recent first quarter were $8.4 million, an increase of 42% over revenues of $5.9 million for the quarter ended March 31, 2001. EPS in the latest quarter grew to $0.10 vs. a loss in the year-ago first quarter.